Todos Medical Ltd (OTCQB:TOMDF) announced on Tuesday that MOTOPARA Foundation’s biosafety level-3 Mobile Labs have achieved clinical validation and CLIA certification to run onsite rapid coronavirus (COVID-19) testing.
In October, Todos struck an exclusive supply agreement with US mobile CLIA lab company Integrated Health LLC, which runs MOTO+PARA Foundation’s mobile labs to battle the coronavirus pandemic.
Todos Medical said Integrated Health LLC has fully validated the clinical performance of the COVID-19 RT-PCR lab testing performed in MOTO+PARA’s mobile labs.
“It has received the approval needed to begin offering COVID-19 screening and analysis as a service to clients anywhere in the US,” said the company. Rapid antigen and antibody testing also have been validated and are now ready to be deployed. MOTO+PARA is prepared to accept contracts from prospective clients immediately, according to Todos.
“We are thrilled to begin testing anywhere in the US and worldwide with our first-of-their-kind mobile labs,” said MOTO+PARA Foundation CEO Eric Canonico.
“With the recent surge of COVID-19 cases, the upcoming holidays predicted to further drive case counts, and the need to pair COVID-19 testing with other tests and emerging vaccination programs, our highly scalable mobile lab solutions are exactly what is needed to address the challenges COVID-19 has placed on existing testing infrastructure.”
MOTO+PARA will deploy rapid antigen and antibody tests, in addition to diagnostic testing with its onsite reverse transcription polymerase chain reaction, or RT-PCR tests, that detect the virus’s genetic material, and turn results around in as little as four hours.
“This allows us to significantly reduce turnaround times for PCR testing and improve the value of each test we provide because the results will be available more quickly than with traditional lab methodologies,” said Integrated Health CEO Jeff Faucheaux.
Todos Medical CEO Gerald E Commissiong noted that deploying all available testing solutions through the country’s first high-complexity mobile labs allowed Todos to assist MOTO+PARA in designing COVID-19 surveillance programs to meet the needs of different constituents who need tests.
“Whether it is making highly sensitive PCR testing available to government entities with turnaround times fast enough to dramatically reduce infection risk, screening fans before entering a stadium for sporting events, or supporting disaster relief efforts to ensure emergency responders are working in a COVID-free environment, we believe these mobile labs are the solution to many of the nation’s testing challenges,” said Commissiong.
“This distribution channel will also allow us to rapidly commercialize emerging novel COVID-19 lab-based testing and monitoring technologies we expect to come to market in the months ahead.”
Headquartered in Rehovot, Israel, with a strong US presence, Todos is an in-vitro diagnostics company focused on solutions for COVID-19 screening and diagnosis, and developing blood tests for the detection of cancer and Alzheimer’s disease.
Contact the author Uttara Choudhury at [email protected]
Follow her on Twitter: @UttaraProactive